← ANALYST RATINGS · TIPRANKS
Celcuity (CELC): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $159, the highest $175, the lowest $134. The average is +181.7% from the last price of $56.58.
Analyst ratings 12
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $65.00 → $61.00−6.2% | Hold | +7.8% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $60.00 → $56.00−6.7% | Hold | −1.0% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $62.00 → $58.00−6.5% | Hold | +2.5% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $60.00 → $57.00−5.0% | Hold | +0.7% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $65.00 → $61.00−6.2% | Hold | +7.8% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $61.00 → $57.00−6.6% | Hold | +0.7% | Reiterated | 17.10.26on TipRanks 17:05 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $155 | Buy | +173.9% | Reiterated | 01.10.26on TipRanks 10:35 | −5.7%next day −4.8% · 5 days −11.0% | ↗ |
| Unknown Analyst | Leerink Partners | $148 → $147−0.7% | Buy | +159.8% | Assigned | 01.10.26on TipRanks 10:35 | −5.7%next day −4.8% · 5 days −11.0% | ↗ |
| Gil Blum★★★★★★★★★★#949 · hits 43% · avg +12.5% | Needham | $140 → $134−4.3% | Buy | +136.8% | Reiterated | 30.09.26on TipRanks 11:50 | +3.0%next day −5.7% · 5 days −19.2% | ↗ |
| Anupam Rama★★★★★★★★★★#291 · hits 54% · avg +23.3% | J.P. Morgan | $157 | Buy | +177.5% | Initiated | 17.09.26on TipRanks 05:42 | +1.7%next day −5.2% · 5 days −7.4% | ↗ |
| Chase Knickerbocker★★★★★★★★★★#75 · hits 59% · avg +36.2% | Craig-Hallum | $178 → $173−2.8% | Buy | +205.8% | Reiterated | 18.08.26on TipRanks 09:10 | +1.5%next day +0.2% · 5 days −0.8% | ↗ |
| Bradley Canino★★★★★★★★★★#1614 · hits 46% · avg +10.8% | Guggenheim | $165 → $175+6.1% | Buy | +209.3% | Assigned | 16.08.26on TipRanks Aug 17 07:20 | +1.0%next day +1.5% · 5 days −0.6% | ↗ |
| Oliver McCammon★★★★★★★★★★#315 · hits 48% · avg +70.9% | LifeSci Capital | $165 | Buy | +191.6% | Reiterated | 14.08.26on TipRanks 13:15 | +6.4%next day +1.0% · 5 days +3.0% | ↗ |
| Stephen Willey★★★★★★★★★★#1608 · hits 45% · avg +8.1% | Stifel Nicolaus | $175 → $150−14.3% | Buy | +165.1% | Reiterated | 14.08.26on TipRanks 07:30 | +6.4%next day +1.0% · 5 days +3.0% | ↗ |
| Eva Fortea Verdejo★★★★★★★★★★#231 · hits 80% · avg +54.1% | Wells Fargo | $166 | Buy | +193.4% | Reiterated | 14.08.26on TipRanks 06:55 | +6.4%next day +1.0% · 5 days +3.0% | ↗ |
| Tara Bancroft★★★★★★★★★★#361 · hits 55% · avg +30.3% | TD Cowen | — | Buy | — | Reiterated | 13.08.26on TipRanks Aug 17 05:56 | −6.6%next day +6.4% · 5 days +6.5% | ↗ |
| Silvan Turkcan★★★★★★★★★★#10721 · hits 17% · avg −13.5% | Citizens JMP | $160 → $177+10.6% | Buy | +212.8% | Reiterated | 15.07.26on TipRanks Jul 23 21:17 | −18.0%next day −3.0% · 5 days −0.5% | ↗ |
| Unknown Analyst | Wolfe Research | $110 | Buy | +94.4% | Initiated | 17.11.25on TipRanks 16:20 | +0.2%next day +2.5% · 5 days +5.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Celcuity
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $160 at a price of $79.52 (+101.1%); now: $158 at $56.58 (+179.3%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 6 | 11 | 18 | 14 | 10 |
| Buy | 24 | 15 | 18 | 4 | 4 | 1 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 18.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.43 (from $-1.75 to $-1.15). Last quarter: $-1.44.
Best top-analyst consensus in the sector · Healthcare
About Celcuity
- CEO: Brian F. Sullivan
- Employees: 155
- 2800 Campus Drive, Minneapolis, MN, 55441, US
- www.celcuity.com
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Data from the stock’s TipRanks forecast page, read 92 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗